Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs acarbose in overweight type 2 diabetes patients on OHA plus high-dose insulin
2010-020193-42Phase 4Terminated
- Sponsor
- Hywel Dda University Health Board
- Start
- Jun 2010
- Modality
- Peptides, Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) and Overweight comparing Liraglutide add-on arm with Acarbose add-on arm (2 arms). Primary endpoint: Change in HbA1c at 52 weeks. Started Jun 2010; status: terminated.
02
Drugs
liraglutideacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)Overweight
Beyond the preview
Go deeper on 2010-020193-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020193-42.